CN113999284A - Cyclic polypeptide for resisting Ebola virus or medicinal salt thereof - Google Patents
Cyclic polypeptide for resisting Ebola virus or medicinal salt thereof Download PDFInfo
- Publication number
- CN113999284A CN113999284A CN202111413917.0A CN202111413917A CN113999284A CN 113999284 A CN113999284 A CN 113999284A CN 202111413917 A CN202111413917 A CN 202111413917A CN 113999284 A CN113999284 A CN 113999284A
- Authority
- CN
- China
- Prior art keywords
- cyclic polypeptide
- polypeptide
- virus
- pep
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 110
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 109
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 108
- 125000004122 cyclic group Chemical group 0.000 title claims abstract description 56
- 241001115402 Ebolavirus Species 0.000 title claims abstract description 49
- 150000003839 salts Chemical class 0.000 title claims abstract description 28
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 22
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 20
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 15
- 125000000539 amino acid group Chemical group 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 229910052721 tungsten Inorganic materials 0.000 claims abstract description 3
- 229910052720 vanadium Inorganic materials 0.000 claims abstract description 3
- 241000700605 Viruses Species 0.000 claims description 44
- 230000002401 inhibitory effect Effects 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 241001115401 Marburgvirus Species 0.000 claims description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 13
- 150000001875 compounds Chemical class 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 13
- 230000000840 anti-viral effect Effects 0.000 claims description 12
- 230000009385 viral infection Effects 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- 208000036142 Viral infection Diseases 0.000 claims description 8
- 238000011282 treatment Methods 0.000 claims description 8
- 239000002202 Polyethylene glycol Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 229920001223 polyethylene glycol Polymers 0.000 claims description 7
- 125000006239 protecting group Chemical group 0.000 claims description 7
- 230000007502 viral entry Effects 0.000 claims description 4
- 238000009098 adjuvant therapy Methods 0.000 claims description 3
- 230000006870 function Effects 0.000 claims description 3
- 150000002634 lipophilic molecules Chemical class 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 claims description 2
- 108010038807 Oligopeptides Proteins 0.000 claims description 2
- 102000015636 Oligopeptides Human genes 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 208000015181 infectious disease Diseases 0.000 abstract description 18
- 210000004027 cell Anatomy 0.000 description 40
- WVTKBKWTSCPRNU-KYJUHHDHSA-N (+)-Tetrandrine Chemical compound C([C@H]1C=2C=C(C(=CC=2CCN1C)OC)O1)C(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2C[C@@H]2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-KYJUHHDHSA-N 0.000 description 26
- 235000002639 sodium chloride Nutrition 0.000 description 22
- 235000001014 amino acid Nutrition 0.000 description 17
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 17
- 241001112090 Pseudovirus Species 0.000 description 16
- 229960001860 salicylate Drugs 0.000 description 16
- 150000001413 amino acids Chemical class 0.000 description 15
- 239000003814 drug Substances 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 14
- 108090000288 Glycoproteins Proteins 0.000 description 13
- 102000003886 Glycoproteins Human genes 0.000 description 13
- 238000000034 method Methods 0.000 description 13
- 125000005609 naphthenate group Chemical group 0.000 description 13
- WVTKBKWTSCPRNU-UHFFFAOYSA-N rac-Tetrandrin Natural products O1C(C(=CC=2CCN3C)OC)=CC=2C3CC(C=C2)=CC=C2OC(=C2)C(OC)=CC=C2CC2N(C)CCC3=CC(OC)=C(OC)C1=C23 WVTKBKWTSCPRNU-UHFFFAOYSA-N 0.000 description 13
- -1 L-form amino acid Chemical class 0.000 description 12
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 11
- 229960003804 efavirenz Drugs 0.000 description 11
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 description 11
- 239000003112 inhibitor Substances 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 9
- 108060001084 Luciferase Proteins 0.000 description 8
- 239000005089 Luciferase Substances 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 239000002552 dosage form Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000005516 engineering process Methods 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 6
- 229920002472 Starch Polymers 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 235000019698 starch Nutrition 0.000 description 6
- 239000008107 starch Substances 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 241001115400 Zaire ebolavirus Species 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000012876 carrier material Substances 0.000 description 5
- 235000019441 ethanol Nutrition 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000003826 tablet Substances 0.000 description 5
- 229960005486 vaccine Drugs 0.000 description 5
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 229910002651 NO3 Inorganic materials 0.000 description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 238000010609 cell counting kit-8 assay Methods 0.000 description 4
- 235000001727 glucose Nutrition 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 3
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- 208000035473 Communicable disease Diseases 0.000 description 3
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 3
- 101710121417 Envelope glycoprotein Proteins 0.000 description 3
- 239000001856 Ethyl cellulose Substances 0.000 description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- 102100034349 Integrase Human genes 0.000 description 3
- 108700008625 Reporter Genes Proteins 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 3
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 3
- 241000711975 Vesicular stomatitis virus Species 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 235000001046 cacaotero Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000010494 dissociation reaction Methods 0.000 description 3
- 230000005593 dissociations Effects 0.000 description 3
- 238000001976 enzyme digestion Methods 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 235000019325 ethyl cellulose Nutrition 0.000 description 3
- 229920001249 ethyl cellulose Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 229940050410 gluconate Drugs 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 229960002900 methylcellulose Drugs 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 239000002002 slurry Substances 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-M 3-carboxy-2,3-dihydroxypropanoate Chemical compound OC(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-M 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 2
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 101150117028 GP gene Proteins 0.000 description 2
- 101900297506 Human immunodeficiency virus type 1 group M subtype B Reverse transcriptase/ribonuclease H Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- TYYLDKGBCJGJGW-UHFFFAOYSA-N L-tryptophan-L-tyrosine Natural products C=1NC2=CC=CC=C2C=1CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 TYYLDKGBCJGJGW-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 108010088535 Pep-1 peptide Proteins 0.000 description 2
- YMTMNYNEZDAGMW-RNXOBYDBSA-N Phe-Phe-Trp Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)O)N YMTMNYNEZDAGMW-RNXOBYDBSA-N 0.000 description 2
- GRVMHFCZUIYNKQ-UFYCRDLUSA-N Phe-Phe-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(O)=O GRVMHFCZUIYNKQ-UFYCRDLUSA-N 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241001115394 Reston ebolavirus Species 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 241001115376 Sudan ebolavirus Species 0.000 description 2
- 241001115374 Tai Forest ebolavirus Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 229910052797 bismuth Inorganic materials 0.000 description 2
- JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- GZUXJHMPEANEGY-UHFFFAOYSA-N bromomethane Chemical compound BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002023 chloroprocaine Drugs 0.000 description 2
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 2
- 229960001231 choline Drugs 0.000 description 2
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 239000003405 delayed action preparation Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000012202 endocytosis Effects 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 2
- 125000001165 hydrophobic group Chemical group 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- 229940099584 lactobionate Drugs 0.000 description 2
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229940070765 laurate Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 229940049920 malate Drugs 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- LRMHVVPPGGOAJQ-UHFFFAOYSA-N methyl nitrate Chemical compound CO[N+]([O-])=O LRMHVVPPGGOAJQ-UHFFFAOYSA-N 0.000 description 2
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 2
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940083575 sodium dodecyl sulfate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 229940095064 tartrate Drugs 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 2
- 125000003831 tetrazolyl group Chemical group 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 108010044292 tryptophyltyrosine Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- FIGBOMZADOQJTB-RZVRUWJTSA-N (2S)-5-amino-2-(methylamino)-5-oxopentanoic acid Chemical compound CN[C@@H](CCC(N)=O)C(=O)O.CN[C@@H](CCC(N)=O)C(=O)O FIGBOMZADOQJTB-RZVRUWJTSA-N 0.000 description 1
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- KVZLHPXEUGJPAH-UHFFFAOYSA-N 2-oxidanylpropanoic acid Chemical compound CC(O)C(O)=O.CC(O)C(O)=O KVZLHPXEUGJPAH-UHFFFAOYSA-N 0.000 description 1
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 1
- 229940117976 5-hydroxylysine Drugs 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000884921 Bundibugyo ebolavirus Species 0.000 description 1
- 101100189913 Caenorhabditis elegans pept-1 gene Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 108091007403 Cholesterol transporters Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- HZZVJAQRINQKSD-UHFFFAOYSA-N Clavulanic acid Natural products OC(=O)C1C(=CCO)OC2CC(=O)N21 HZZVJAQRINQKSD-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- XRTISHJEPHMBJG-SRVKXCTJSA-N Cys-Asp-Tyr Chemical compound SC[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 XRTISHJEPHMBJG-SRVKXCTJSA-N 0.000 description 1
- AOZBJZBKFHOYHL-AVGNSLFASA-N Cys-Glu-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O AOZBJZBKFHOYHL-AVGNSLFASA-N 0.000 description 1
- DIUBVGXMXONJCF-KKUMJFAQSA-N Cys-His-Tyr Chemical compound [H]N[C@@H](CS)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O DIUBVGXMXONJCF-KKUMJFAQSA-N 0.000 description 1
- ZKAUCGZIIXXWJQ-BZSNNMDCSA-N Cys-Tyr-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)NC(=O)[C@H](CS)N)O ZKAUCGZIIXXWJQ-BZSNNMDCSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 208000030820 Ebola disease Diseases 0.000 description 1
- 241000711950 Filoviridae Species 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 1
- 206010069803 Injury associated with device Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 108010028921 Lipopeptides Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- CYZKJBZEIFWZSR-LURJTMIESA-N N(alpha)-methyl-L-histidine Chemical compound CN[C@H](C(O)=O)CC1=CNC=N1 CYZKJBZEIFWZSR-LURJTMIESA-N 0.000 description 1
- 108700018419 Niemann-Pick C1 Proteins 0.000 description 1
- 108090001074 Nucleocapsid Proteins Proteins 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000009435 amidation Effects 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- JUHORIMYRDESRB-UHFFFAOYSA-N benzathine Chemical compound C=1C=CC=CC=1CNCCNCC1=CC=CC=C1 JUHORIMYRDESRB-UHFFFAOYSA-N 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- BGTFCAQCKWKTRL-YDEUACAXSA-N chembl1095986 Chemical compound C1[C@@H](N)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H]1C(N[C@H](C2=CC(O)=CC(O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=C2C=2C(O)=CC=C(C=2)[C@@H](NC(=O)[C@@H]2NC(=O)[C@@H]3C=4C=C(C(=C(O)C=4)C)OC=4C(O)=CC=C(C=4)[C@@H](N)C(=O)N[C@@H](C(=O)N3)[C@H](O)C=3C=CC(O4)=CC=3)C(=O)N1)C(O)=O)=O)C(C=C1)=CC=C1OC1=C(O[C@@H]3[C@H]([C@H](O)[C@@H](O)[C@H](CO[C@@H]5[C@H]([C@@H](O)[C@H](O)[C@@H](C)O5)O)O3)O[C@@H]3[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O[C@@H]3[C@H]([C@H](O)[C@@H](CO)O3)O)C4=CC2=C1 BGTFCAQCKWKTRL-YDEUACAXSA-N 0.000 description 1
- XHRPOTDGOASDJS-UHFFFAOYSA-N cholesterol n-octadecanoate Natural products C12CCC3(C)C(C(C)CCCC(C)C)CCC3C2CC=C2C1(C)CCC(OC(=O)CCCCCCCCCCCCCCCCC)C2 XHRPOTDGOASDJS-UHFFFAOYSA-N 0.000 description 1
- XHRPOTDGOASDJS-XNTGVSEISA-N cholesteryl stearate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCCCCCCCCCCCC)C1 XHRPOTDGOASDJS-XNTGVSEISA-N 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 229940090805 clavulanate Drugs 0.000 description 1
- HZZVJAQRINQKSD-PBFISZAISA-N clavulanic acid Chemical compound OC(=O)[C@H]1C(=C/CO)/O[C@@H]2CC(=O)N21 HZZVJAQRINQKSD-PBFISZAISA-N 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- ACYGYJFTZSAZKR-UHFFFAOYSA-J dicalcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Ca+2].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O ACYGYJFTZSAZKR-UHFFFAOYSA-J 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- UFCZCJYLUGMEJH-UHFFFAOYSA-N dodecanoic acid;propanoic acid Chemical compound CCC(O)=O.CCCCCCCCCCCC(O)=O UFCZCJYLUGMEJH-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 229950005627 embonate Drugs 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- 229950000206 estolate Drugs 0.000 description 1
- AFAXGSQYZLGZPG-UHFFFAOYSA-L ethane-1,2-disulfonate Chemical compound [O-]S(=O)(=O)CCS([O-])(=O)=O AFAXGSQYZLGZPG-UHFFFAOYSA-L 0.000 description 1
- 229960004667 ethyl cellulose Drugs 0.000 description 1
- 229940071106 ethylenediaminetetraacetate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000007499 fusion processing Methods 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- 229940073769 methyl oleate Drugs 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- ACTNHJDHMQSOGL-UHFFFAOYSA-N n',n'-dibenzylethane-1,2-diamine Chemical compound C=1C=CC=CC=1CN(CCN)CC1=CC=CC=C1 ACTNHJDHMQSOGL-UHFFFAOYSA-N 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-M naphthalene-1-sulfonate Chemical compound C1=CC=C2C(S(=O)(=O)[O-])=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-M 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000013307 optical fiber Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 229940014662 pantothenate Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000007110 pathogen host interaction Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 210000004896 polypeptide structure Anatomy 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000012460 protein solution Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- PYDGNVZQEUTTKV-UHFFFAOYSA-M sodium 4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-1,3-dihydrotetrazol-3-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COc1cc(ccc1N1NC(=N[NH+]1c1ccc(cc1)[N+]([O-])=O)c1ccc(cc1S([O-])(=O)=O)S([O-])(=O)=O)[N+]([O-])=O PYDGNVZQEUTTKV-UHFFFAOYSA-M 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- VSIVTUIKYVGDCX-UHFFFAOYSA-M sodium;4-[2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].COC1=CC([N+]([O-])=O)=CC=C1[N+]1=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=NN1C1=CC=C([N+]([O-])=O)C=C1 VSIVTUIKYVGDCX-UHFFFAOYSA-M 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 230000003319 supportive effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229940044959 vaginal cream Drugs 0.000 description 1
- 229940044950 vaginal gel Drugs 0.000 description 1
- 229940098946 vaginal ointment Drugs 0.000 description 1
- 229940044953 vaginal ring Drugs 0.000 description 1
- 239000006213 vaginal ring Substances 0.000 description 1
- 229940120293 vaginal suppository Drugs 0.000 description 1
- 239000006216 vaginal suppository Substances 0.000 description 1
- 229940070710 valerate Drugs 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses a cyclic polypeptide or a medicinal salt thereof for resisting Ebola virus. The amino acid sequence of the cyclic polypeptide is shown as the following (formula I): x1X2X3X4X5X6X7X8(formula I) wherein X1To X8Are each an amino acid residue, said X1Is C, the X2Is E, D, H or Y, the X3Is Y, said X4Is F, the X5Is F, the X6Is W or V, said X7Is Y or H, said X8Is C; x in (formula I)1And X8Form disulfide bonds to form a ring. The cyclic polypeptide can be combined with a target protein EBOV-GPcl so as to specifically inhibit Ebola virus from entering cells, and the effect of resisting EBOV infection is achieved.
Description
The application is a divisional application with the application number of 2020104602227, the original application has the application number of 201810087839.1, the application date of 2018, and the date of 30 and 01, and the invention and creation name of the application is 'polypeptide specifically combined with the envelope glycoprotein in an activated state of the ebola virus and the application thereof in resisting viruses'.
Technical Field
The invention relates to cyclic polypeptide or medicinal salt thereof for resisting Ebola virus in the technical field of medicine.
Background
Ebola virus (formerly known as Ebola hemorrhagic fever) is an acute hemorrhagic infectious disease caused by Ebola virus (EBOV) of the family filoviridae, with a mortality rate as high as 90%, one of the most fatal viral infectious diseases of humans. EBOV can be classified into 5 types, Zaire type (Zaire ebolavirus, Zaire-EBOV, ZEBOV), Sudan type (Sudan ebolavirus, SUDV), Tay Forest type (Tai Forest ebolavirus, TAFV), Bendiumbu Joule type (BDBV), and Riston type (RESton ebolavirus, RESTV). Among them, the zaire ebola virus is most virulent. At present, symptomatic and supportive treatment is mainly adopted for EBOV infection, and no specific treatment medicament and vaccine which are effective through systemic clinical verification exist. With the increase of global population mobility and the existence of EBOV superspread as well as the characteristics of strong pathogenicity and easy genetic variation of the virus, EBOV becomes a potential global health threat. Therefore, there is a need to develop anti-EBOV drugs with definite targets and novel structural types, and to ensure the ability to prevent EBOV infections and outbreaks of new infectious diseases.
The EBOV is a single-stranded negative-strand RNA virus, the outermost layer of which is enveloped by a viral envelope, and the center of which is a helical nucleocapsid. The genome is about 18.9kb in length, encodes seven structural proteins, and has the gene sequence of 3-NP-VP35-VP40-GP-VP30-VP 24-L-5. Among them, the envelope Glycoprotein (GP) is the only protein responsible for the entry of the virus into the host cell. Whether coated on the surface of the virus or shed from infected cells during infection, GP can participate in a variety of immune response reactions, plays an important role in the viral life cycle and host-pathogen interactions, and is a potential effective target for inhibiting EBOV infection. Since the entry stage of the virus is the first and indispensable step in the virus replication cycle, blocking the EBOV-GP mediated virus entry will effectively inhibit virus infection and cytotoxicity caused by the virus infection, and also reduce the occurrence of drug resistance. The EBOV-GP can be subjected to enzyme digestion after entering lysosome, and activated glycoprotein (Primed GP, GPcl) after enzyme digestion can directly interact with endocytosis receptor-human cholesterol transporter (Niemann-Pick C1, NPC1), so that a membrane fusion process between the virus and host cells is initiated.
Disclosure of Invention
The invention aims to solve the technical problem of specifically inhibiting the Ebola virus from entering cells so as to resist EBOV infection.
In order to solve the above technical problems, the present invention provides a cyclic polypeptide or a pharmaceutically acceptable salt thereof.
In the cyclic polypeptide or the medicinal salt thereof provided by the invention, the amino acid sequence of the cyclic polypeptide is shown as the following (formula I):
X1X2X3X4X5X6X7X8(formula I) is shown in the specification,
in the formula I, X1To X8Are each an amino acid residue, said X1Is C, the X2Is E, D, H or Y, the X3Is Y, said X4Is F, the X5Is F, the X6Is W or V, said X7Is Y or H, said X8Is C; x in (formula I)1And X8Form disulfide bonds to form a ring.
In the above cyclic polypeptide or its medicinal salt, the cyclic polypeptide can be Pep-3.3, Pep-3.2, Pep-3.1 or Pep-3.10; the amino acid sequence of the Pep-3.3 is SEQ ID No.1 in the sequence table, the amino acid sequence of the Pep-3.2 is SEQ ID No.2 in the sequence table, the amino acid sequence of the Pep-3.1 is SEQ ID No.3 in the sequence table, and the amino acid sequence of the Pep-3.10 is SEQ ID No.4 in the sequence table.
Derivatives of the above cyclic polypeptides also fall within the scope of the present invention.
The derivative of the cyclic polypeptide can be d1, d2, d3, d4 or d 5; the d1 is a connector obtained by connecting an amino terminal protecting group at the amino terminal of the cyclic polypeptide and/or connecting a carboxyl terminal protecting group at the carboxyl terminal of the cyclic polypeptide;
d2 is a polypeptide which is obtained by adding amino acid residues at the amino terminal and/or the carboxyl terminal of the cyclic polypeptide and can be specifically combined with GPcl (virus activated envelope glycoprotein);
d3 is a polypeptide which is obtained by connecting oligopeptide at the amino terminal and/or the carboxyl terminal of the cyclic polypeptide and can be specifically combined with GPcl;
the d4 is a modified substance obtained by modifying the cyclic polypeptide by protein, polyethylene glycol or maleimide;
the d5 is a polypeptide which is obtained by connecting a lipophilic compound at the amino terminal and/or the carboxyl terminal of the cyclic polypeptide and can be specifically combined with GPcl.
The following multimers of PM1 or PM2 are also within the scope of the invention:
PM1, multimers formed from the cyclic polypeptides or pharmaceutically acceptable salts thereof;
PM2, multimers formed by said derivatives.
In the above cyclic polypeptide, a pharmaceutically acceptable salt thereof, or a derivative thereof, each capital letter in the sequence of the cyclic polypeptide is an abbreviation for an amino acid, which has a meaning well known in the art, for example: c is cysteine, D is aspartic acid, E is glutamic acid, Y is tyrosine, F is phenylalanine, W is tryptophan, V is valine, H is histidine, etc. All amino acids in the cyclic polypeptide sequence may be L-type amino acids, and one or more (e.g., 2-5, 2-4, or 2-3) amino acids may also be replaced with D-type amino acids, artificially modified amino acids, naturally occurring rare amino acids, and the like, to improve the bioavailability, stability, and/or antiviral activity of the cyclic polypeptide. Wherein the D-form amino acid is an amino acid corresponding to the L-form amino acid constituting the protein; the artificially modified amino acid refers to common L-type amino acid which is modified by methylation, phosphorylation and the like and forms protein; the rare amino acids existing in nature include unusual amino acids constituting proteins and amino acids not constituting proteins, such as 5-hydroxylysine, methylhistidine, gamma-aminobutyric acid, homoserine and the like.
In the cyclic polypeptide, the pharmaceutically acceptable salt thereof, or the derivative thereof, the lipophilic compound may be bonded to a side chain of a terminal amino acid or may be directly bonded to a peptide chain.
In the above cyclic polypeptide, its pharmaceutically acceptable salt, or its derivative, the amino terminal of the cyclic polypeptide of the present invention may contain an amino terminal protecting group, wherein the amino terminal protecting group may be any one of acetyl, amino, maleoyl, succinyl, tert-butoxycarbonyl, or benzyloxy, or other hydrophobic group or macromolecular carrier group; the carboxyl terminus of the cyclic polypeptide of the invention may contain a carboxyl-terminal protecting group, which may be any of an amino, amide, carboxyl, or tert-butoxycarbonyl group or other hydrophobic group or a macromolecular carrier group.
Compositions comprising C1) and C2) below also belong to the scope of protection of the present invention: C1) is C11), C12) or/and C13); c11) is the cyclic polypeptide or the medicinal salt thereof; c12) is the derivative; the C13) is the polymer;
C2) a pharmaceutically acceptable carrier or adjuvant;
the composition has at least one of the following functions F1) -F3):
F1) resisting viruses;
F2) treating and/or preventing and/or adjunctively treating diseases caused by viral infection;
F3) inhibiting the entry of virus into cells.
In the above composition, said F1) -F3), said virus may be ebola virus (zaire type, sudan type, tay forest type, bundbox type and/or leston type), or marburg virus (MARV).
The application of the C11), the C12), the C13) or/and the C14) in the preparation of at least one product of E1) to E3) also belongs to the protection scope of the invention:
c14) is the composition;
e1) is an antiviral product, such as a drug or vaccine;
e2) is a product for the treatment and/or prophylaxis and/or adjuvant treatment of diseases caused by viral infections, such as drugs or vaccines;
e3) is a product that inhibits the entry of a virus into a cell, such as a drug or vaccine;
in the above applications, the virus in E1) -E3) may be ebola virus (zaire type, sudan type, tay forest type, bundbox type and/or leston type), or marburg virus.
The present invention provides pharmaceutical compounds.
The medicinal compound provided by the invention is the C11), C12) or C13).
The medicinal compound has at least one of the following U1) -U3):
u1) for antiviral;
u2) for the treatment and/or prophylaxis and/or adjuvant treatment of diseases caused by viral infections;
u3) for inhibiting virus entry into cells.
U1) -U3) of the above pharmaceutical compound, the virus may be ebola virus (zaire, sudan, tay forest, bundbox and/or leston), or marburg virus.
As described above, the inhibiting of viral entry into a cell may be inhibiting GPcl-mediated viral entry into a cell.
Pharmaceutically acceptable salts of the cyclic polypeptides of the invention include acetate (acetate), lactobionate (lactobionate), benzenesulfonate (benzamate), laurate (laurate), benzoate (benzoate), malate (malate), bicarbonate (bicarbonate), maleate (maleate), bisulfate (bisulfate), mandelate (mandelate), bitartrate (bitartrate), mesylate (mesylate), borate (borate), methyl bromide (methybromide), bromide (bromide), methyl nitrate (methylnitrate), calcium edetate), methylsulfate (methylsulfate), dexcamphorsulfonate (camsylate), mucate (mucate), carbonate (carbonate), naphthalenesulfonate (napsylate), chloride (chloride), nitrate (nitrate), clavulanate (nitrate), propionate (nitrate), N-methyl-oleate (citrate), N-methylgluconate (ammonium dihydrooleate), dihydrooleate (ammonium dihydrooleate), ethylenediaminetetraacetate (acetate), oxalate (oxalate), ethanedisulfonate (edisylate), pamoate (pamoate) (embonate), propionate laurate (estolate), palmitate (palmoate), ethanesulfonate (esylate), pantothenate (panthenate), fumarate (fumarate), phosphate/diphosphate (phosphate/diphosphate), glucoheptonate (gluconate), polygalacturonate (polygalacturonate), gluconate (gluconate), salicylate (salicylate), glutamate (glutamate), stearate (stearate), glycollylarsanilate (glycolurilate), sulfate (sulfate), hydroxybenzoate (hexedronate), subacetate (subacetate), hydrabamine (hydrabamine), succinate (succinylate), hydrobromide (hydrobromide), salicylate (salicylate), salicylate (salicylate), salicylate (salicylate), salicylate (salicylate), sulfate (salicylate), salicylate (sulfate), salicylate), sulfate (sulfate), salicylate), sulfate (sulfate), salicylate (sulfate), salicylate (tartrate), naphthenate), (tartrate), naphthenate (naphthenate), naphthenate (naphthenate), naphthenate (naphthenate), naphthenate (hydrochloride (naphthenate), naphthenate (naphthenate), naphthenate (naphthenate), iodide (iodide), tosylate (tosylate), triiodode (triiodode), lactic acid (lactate), valeric acid (valerate), and the like. Depending on the use, pharmaceutically acceptable salts may be formed from cations such as sodium (sodium), potassium (potassium), aluminum (aluminum), calcium (calcium), lithium (lithium), manganese (magnesium), and zinc (zinc), bismuth (bismuth), and the like, or bases such as ammonia, ethylenediamine (ethylenediamine), N-methyl-glutamine (N-methyl-glutamine), lysine (lysine), arginine (arginine), ornithine (ornithine), choline (choline), N '-dibenzylethylenediamine (N, N' -dibenzylethylenediamine), chloroprocaine (chloroprocaine), diethanolamine (diethanolamine), procaine (procaine), diethylamine (diethylamine), piperazine (piperazine), tris (hydroxymethyl) aminomethane (trimethyl), tetramethylammonium hydroxide (hydroxide), and the like. These salts can be prepared by standard methods, for example by reaction of the free acid with an organic or inorganic base. In the presence of a basic group such as an amino group, an acidic salt such as hydrochloride, hydrobromide, acetate, pamoate and the like may be used as the dosage form; pharmaceutically acceptable esters such as acetate (acetate), maleate (maleate), chloromethyl (pivaloyloxymethyl) acetate, and the like, and esters known in the literature for improving solubility and hydrolyzability in the presence of an acidic group such as-COOH or an alcohol group, can be used as sustained release and prodrug formulations.
The cyclic polypeptide, the derivative thereof, or the pharmaceutically acceptable salt thereof, the multimer, the composition or the pharmaceutically acceptable compound provided by the invention can be used for treating EBOV and/or MARV infection. The lipopeptides or polypeptides, derivatives thereof, or pharmaceutically acceptable salts thereof, the multimers, the compositions or the pharmaceutical compounds provided herein may also be used in the prevention of EBOV and/or MARV infection, including pre-or post-suspected exposure to, for example, blood transfusion, organ transplantation, exchange of body fluids, bite, accidental needle stick or surgical exposure to the patient's blood, and the like.
In practice, the cyclic polypeptide, its derivative, or a pharmaceutically acceptable salt thereof, the multimer, the composition or the pharmaceutical compound of the present invention may be administered as a medicament directly to a patient, or may be administered to a patient after mixing with a suitable carrier or excipient, for the purpose of treating and/or preventing an EBOV and/or MARV infection. The carrier material herein includes, but is not limited to, water-soluble carrier materials (e.g., polyethylene glycol, polyvinylpyrrolidone, organic acids, etc.), poorly soluble carrier materials (e.g., ethyl cellulose, cholesterol stearate, etc.), enteric carrier materials (e.g., cellulose acetate phthalate, carboxymethyl cellulose, etc.). Among these, water-soluble carrier materials are preferred. The materials can be prepared into various dosage forms, including but not limited to tablets, capsules, dripping pills, aerosols, pills, powders, solutions, suspensions, emulsions, granules, liposomes, transdermal agents, buccal tablets, suppositories, freeze-dried powder injections and the like. Wherein the suppository can be vaginal suppository, vaginal ring, ointment, cream or gel suitable for vaginal application. Can be common preparation, sustained release preparation, controlled release preparation and various microparticle drug delivery systems. In order to prepare the unit dosage form into tablets, various carriers well known in the art can be widely used. Examples of the carrier are, for example, diluents and absorbents such as starch, dextrin, calcium sulfate, lactose, mannitol, sucrose, sodium chloride, glucose, urea, calcium carbonate, kaolin, microcrystalline cellulose, aluminum silicate and the like; wetting agents and binders such as water, glycerin, polyethylene glycol, ethanol, propanol, starch slurry, dextrin, syrup, honey, glucose solution, acacia slurry, gelatin slurry, sodium carboxymethylcellulose, shellac, methyl cellulose, potassium phosphate, polyvinylpyrrolidone and the like; disintegrating agents such as dried starch, alginate, agar powder, brown algae starch, sodium bicarbonate and citric acid, calcium carbonate, polyoxyethylene, sorbitol fatty acid ester, sodium dodecylsulfate, methyl cellulose, ethyl cellulose, etc.; disintegration inhibitors such as sucrose, glyceryl tristearate, cacao butter, hydrogenated oil and the like; absorption accelerators such as quaternary ammonium salts, sodium lauryl sulfate and the like; lubricants, for example, talc, silica, corn starch, stearate, boric acid, liquid paraffin, polyethylene glycol, and the like. The tablets may be further formulated into coated tablets, such as sugar-coated tablets, film-coated tablets, enteric-coated tablets, or double-layer and multi-layer tablets. In order to prepare the dosage form for unit administration into a pill, various carriers well known in the art can be widely used. Examples of the carrier are, for example, diluents and absorbents such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, kaolin, talc and the like; binders such as acacia, tragacanth, gelatin, ethanol, honey, liquid sugar, rice paste or batter, etc.; disintegrating agents, such as agar powder, dried starch, alginate, sodium dodecylsulfate, methylcellulose, ethylcellulose, etc. In order to prepare the unit dosage form into suppositories, various carriers known in the art can be widely used. As examples of the carrier, there may be mentioned, for example, polyethylene glycol, lecithin, cacao butter, higher alcohols, esters of higher alcohols, gelatin, semisynthetic glycerides and the like. In order to prepare the unit dosage form into preparations for injection, such as solutions, emulsions, lyophilized powders and suspensions, all diluents commonly used in the art, for example, water, ethanol, polyethylene glycol, 1, 3-propanediol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitol fatty acid esters, etc., can be used. In addition, for the preparation of isotonic injection, sodium chloride, glucose or glycerol may be added in an appropriate amount to the preparation for injection, and conventional cosolvents, buffers, pH adjusters and the like may also be added. In addition, colorants, preservatives, flavors, flavorings, sweeteners or other materials may also be added to the pharmaceutical preparation, if desired.
The preparation can be used for injection administration, including subcutaneous injection, intravenous injection, intramuscular injection, intraperitoneal injection, intracisternal injection or infusion, and the like; for buccal administration, e.g., rectally, vaginally, and sublingually; administration to the respiratory tract, e.g., nasally; administration to the mucosa. The above route of administration is preferably by injection, and the preferred route of injection is subcutaneous injection.
The cyclic polypeptide, its derivative, a pharmaceutically acceptable salt, said multimer, said composition or said pharmaceutically acceptable compound of the present invention is administered in a dose depending on many factors, such as the nature and severity of the disease to be prevented or treated, sex, age, body weight and individual response of the patient or animal, the specific active ingredient used, the administration route and the number of administrations, etc. The above-mentioned dosage may be administered in a single dosage form or divided into several, e.g. two, three or four dosage forms.
For any particular patient, the specific therapeutically effective dose level will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the particular active ingredient employed; the specific composition employed; the age, weight, general health, sex, and diet of the patient; the time of administration, route of administration and rate of excretion of the particular active ingredient employed; the duration of treatment; drugs used in combination or concomitantly with the specific active ingredient employed; and similar factors known in the medical arts. For example, it is common in the art to start doses of the active ingredient at levels below those required to achieve the desired therapeutic effect and to gradually increase the dose until the desired effect is achieved.
The cyclic polypeptide, the derivative thereof or the pharmaceutically acceptable salt thereof, the polymer, the composition or the pharmaceutically acceptable compound can be directly and independently used for treating and preventing EBOV and/or MARV infected persons, can also be used together with one or more anti-EBOV and/or MARV infection medicaments, and can be used simultaneously or at intervals so as to achieve the aim of improving the overall treatment effect.
In the present invention, the antiviral activity may also be referred to as inhibition of viral activity, and specifically may be inhibition of viral entry into cells.
Experiments prove that the cyclic polypeptide can specifically inhibit the Ebola virus from entering cells. The cyclic polypeptide can be combined with a target protein EBOV-GPcl so as to specifically inhibit Ebola virus from entering cells, and the effect of resisting EBOV infection is achieved. The cyclic polypeptide or the medicinal salt and the derivative thereof can be used as a novel EBOV entry inhibitor and can be applied to developing anti-EBOV vaccines or medicaments.
Drawings
FIG. 1 shows that Pep-3.1, Pep-3.2, Pep-3.3 and Pep-3.10 can specifically inhibit the activity of EBOV-Zaire GP/HIV-luc recombinant viruses. In FIG. 1, VSVG represents VSV-G/HIV-luc, Ebola-GP represents EBOV-GP/HIV-luc, and the viral infection rate is 1-inhibition rate.
FIG. 2 is a graph showing the effect of the polypeptide on the growth of 293T cells in a cell growth experiment.
FIG. 3 shows that Pep-3.1, Pep-3.2, Pep-3.3 and Pep-3.10 have good dose-dependence on the inhibition of EBOV-Zaire GP/HIV-luc recombinant virus.
FIG. 4 is a time point experiment of drug action, which shows that the polypeptide Pep-3.3 acts on the entry stage of virus.
FIG. 5 is the dynamic binding curve of polypeptides Pep-3.1, Pep-3.2, Pep-3.3 and Pep-3.10 and target protein GPcl measured in vitro by using the biomembrane optical interference technique. In the figure, the arrows indicate the concentration of each sample.
Detailed Description
The invention is realized by the following technical scheme:
first, a structure-based polypeptide drug design was performed using the loop structure (amino acid sequence DDFFVY) at the C-terminus of domain of NPC1 as a template. To increase the stability of the polypeptide and to protect it from phosphatase attack, a cysteine, and thereby a disulfide bond, is introduced at each of the head and tail ends of the amino acid sequence. And then, amidation modification is carried out on the carbon terminal, and acetylation modification is carried out on the nitrogen terminal to further improve the stability of the polypeptide. When the polypeptide structure is Ac-cyclo (CDDFFVYC) -NH2. In order to improve the binding capacity of the polypeptide and the target protein EBOV-GPcl, the structure of the polypeptide is further optimized by constructing single-point, double-point and three-point amino acid mutation, so as to obtain the optimal combination sequence of the polypeptide. Then, the designed polypeptide is docked into the target protein GPcl, and the polypeptide with better free energy (Table 1) is selected for solid phase synthesis.
EBOV is classified as a dangerous quaternary virus, and therefore the polypeptide is evaluated for biological activity at the in vitro level using a safe and effective study approach, pseudovirus technology. The most toxic GP protein of the zaire-type EBOV is used for wrapping an HIV core to prepare the replication-defective pseudovirus EBOV-GP/HIV-luc, and the antiviral activity of a sample is judged by a fluorescent reporter gene detection technology. At the same time, the specificity of the polypeptides was analyzed using the VSVG/HIV-luc recombinant virus model. After eliminating cytotoxicity, the action mechanism of the polypeptide is further verified by adopting a drug action time point experiment. And finally, determining the binding capacity of the polypeptide and the target protein GPcl in vitro by using a biomembrane optical interference technology based on the optical fiber biosensor, and verifying the targeting property of the polypeptide.
All polypeptides in Table 1 have an amino-terminal homoacetylation modification (Ac-), and a carboxyl-terminal homoamidation modification (-NH)2). "Cyclo" indicates that the amino acid sequence in parentheses forms a cyclic polypeptide by the amino acid residue at position 1 and the amino acid residue at position 1 last. In Pep-1, the amino acid sequence in brackets is connected with the amino acid residue at the last position 1 through an amido bond to form a cyclic polypeptide through the amino acid residue at the position 1; in Pep-3, Pep-3.1, Pep-3.2, Pep-3.3, Pep-3.6, Pep-3.7 and Pep-3.10, the amino acid sequence in parentheses is linked to the amino acid residue at the last position 1 through the formation of a disulfide bond to form a cyclic polypeptide.
TABLE 1 sequence Structure of the Polypeptides
Name (R) | Sequence structure |
Pep-1 | Ac-cyclo(DDFFVY)-NH2 |
Pep-2 | Ac-DDFFVY-NH2 |
Pep-3 | Ac-cyclo(CDDFFVYC)-NH2 |
Pep-3.1 | Ac-cyclo(CHYFFVYC)-NH2 |
Pep-3.2 | Ac-cyclo(CDYFFWYC)-NH2 |
Pep-3.3 | Ac-cyclo(CEYFFWYC)-NH2 |
Pep-3.6 | Ac-cyclo(CDRFFVYC)-NH2 |
Pep-3.7 | Ac-cyclo(CDYFFRYC)-NH2 |
Pep-3.10 | Ac-cyclo(CYYFFVHC)-NH2 |
The polypeptides of table 1 were all synthesized by beijing september gene technology ltd with a purity > 98%. The specific acquisition means is the prior art, and the present invention is not particularly limited thereto.
The present invention is described in further detail below with reference to specific embodiments, which are given for the purpose of illustration only and are not intended to limit the scope of the present invention. Although the antiviral mechanism of the present invention is specifically illustrated below by referring to zaire type EBVO, the scope of the present invention for the use of polypeptides is not limited to EBOV. Any virus that is amenable to the above antiviral mechanisms is within the scope of the invention, e.g., the other four subtypes of EBOV and MARV, etc.
In addition, it should be noted that, unless otherwise specified, various materials and reagents used in the following examples are those commonly used in the art and are commercially available in a usual manner; the methods used are conventional methods known to the person skilled in the art or according to the conditions recommended by the manufacturers.
Example 1, EBOV entry inhibitor screening model demonstrated that Pep-3.1, Pep-3.2, Pep-3.3, and Pep-3.10 were able to specifically inhibit EBOV activity.
The GP of Zaire-EBOV and HIV core plasmid (pNL4-3.Luc) are co-expressed by utilizing a cell level recombinant virus technology to prepare a recombinant virus (EBOV-GP/HIV-Luc), and the antiviral activity of the polypeptide is evaluated by applying a high-throughput screening model of EBOV entry inhibitors targeting GP proteins. The method comprises the following specific steps:
293T cells were cultured, and after the cells grew in the culture flask, the old medium was discarded and digested with a digestive solution containing 0.25% pancreatin and 0.02% EDTA. After the cells became round, the digestive juice was discarded, and a high-glucose DMEM medium (gibioco) containing 10% FBS (purchased from GIBCO) was immediately added, and the bottom of the flask was gently blown with a pipette to completely detach the cells from the bottom of the flask and disperse them into a single-cell suspension. After counting, the cell concentration was adjusted to 2.2X 10 with the medium5one/mL, seeded in 6-well plates, 2 mL/well. After 24h (cell abundance about 70%) transfection, plasmid amount: mu.g of pZEBOV-GP and 3. mu.g of the HIV-luc plasmid pNL4-3. Luc.R-E-carrying the luciferase reporter gene, the transfection reagent is Lipofectamine2000 (Invitrogen), and the transfection is carried out according to the instructions to generate the Ebola pseudotype virus, which is designated EBOV-GP/HIV-luc or EBOV-Zaire GP/HIV-luc. Supernatants containing pseudotyped virus were collected 48 hours post transfection, pooled, clarified from floating cells and cell debris by low speed centrifugation, and filtered through a 0.45 μm pore size filter. Pseudovirions were quantified by measuring virus-associated HIV p24 levels using an ELISA assay.
Wherein pZEBOV-GP is a recombinant expression plasmid for expressing the Glycoprotein (GP) of Zaire-EBolavirus isolate H.sapiens-wt/GIN/2014/Makona-Gueckedou-C07, which is obtained by inserting the GP gene of Zaire-ebola virus isolate H.sapiens-wt/GIN/2014/Makona-Gueckedou-C07 (position 5900-8305 of GenBank Accession No. KJ660347(Update Date Dec 18,201401: 25PM) into the vector pcDNA3.1 (+).
EBOV-GP/HIV-luc pseudovirus particles were incubated with 293T cells in 96-well plates. After 48 hours, the cells were harvested and lysed to measure firefly luciferase activity. The value of luciferase activity represents viral infection.
The polypeptides in Table 1 were dissolved in DMSO respectively, mixed with EBOV-GP/HIV-luc pseudovirus respectively, and added to 293T cells to give a polypeptide content of 10. mu.M in Table 1. After 48 hours, 293T cells were lysed and the rate of viral inhibition by the polypeptide was assessed by measuring luciferase activity. Solvent DMSO was used as a blank control (DMSO), while EBOV entry inhibitors tetrandrine (TET) and HIV-1 reverse transcriptase inhibitor efavirenz (efavirenz, EFV) were introduced as controls. The tetrandrine and the efavirenz are respectively dissolved by DMSO and then respectively mixed with EBOV-GP/HIV-luc pseudovirus to be added into 293T cells, and the content of the tetrandrine and the efavirenz is 1 mu M. After 48 hours, 293T cells were lysed and the rate of viral inhibition by the polypeptide was assessed by measuring luciferase activity.
Most of the currently known EBOV inhibitors are broad-spectrum antiviral drugs, and specific analysis of the screened active polypeptides is required in order to search for a narrow-spectrum inhibitor against EBOV. Since vesicular stomatis virus coat glycoprotein (VSVG) and EBOV-GPcl play an important role in recognition of viruses and receptors due to similar effects, the screened active polypeptides were specifically analyzed using pseudoviruses expressing VSV-GP. After eliminating the cytotoxicity factor, the inhibition activity of the active polypeptide on VSV-G/HIV-luc pseudovirus is detected by using the luciferase principle, and the method is the same as the above. If the polypeptide only has obvious inhibition effect on EBOV-GPcl mediated virus entry, but has no inhibition or low inhibition rate on VSV, the polypeptide has specificity on EBOV.
As shown in FIG. 1, the inhibition ratio of Pep-3.1, Pep-3.2, Pep-3.3 and Pep-3.10 on EBOV-GP/HIV-luc pseudovirus was higher than 80%, but the inhibition ratio on VSV-G/HIV-luc pseudovirus was lower than 50% at the same concentration. This indicates that Pep-3.1, Pep-3.2, Pep-3.3 and Pep-3.10 have specific inhibitory effects on EBOV-GP/HIV-luc pseudoviruses. Among them, the specific inhibition of Pep-3.3 is the most obvious. The EBOV entry inhibitor tetrandrine (TET), a positive control, had a selective inhibitory effect similar to that of the active polypeptide, whereas the HIV-1 reverse transcriptase inhibitor Efavirenz (EFV) had an inhibitory effect on both pseudoviruses.
Wherein, the preparation method of pseudovirus VSV-G/HIV-luc expressing VSV-GP is different from the preparation method of EBOV-GP/HIV-luc only in that pZEBOV-GP in the preparation method of EBOV-GP/HIV-luc is replaced by pVSV-GP, and other operations are completely the same. pVSV-GP is a recombinant expression plasmid for expressing vesicular stomatitis virus coat glycoprotein, which is obtained by inserting 14 th to 1567 th sites of the GP gene of vesicular stomatitis virus coat glycoprotein (GenBank Accession No. V01214(Update Date Feb 4,2011)) into the vector pcDNA3.1 (+).
The antiviral activity of example 2, Pep-3.1, Pep-3.2, Pep-3.3 and Pep-3.10 was not associated with its cytotoxicity.
To exclude non-specific differences due to polypeptide toxicity, the effect of the polypeptide on 293T cell growth was assessed using the cell Counting Kit-8 (ell Counting Kit-8, CCK-8).
The CCK-8 kit is a kit for detecting cell proliferation, cell survival and cytotoxicity, is a widely-applied rapid high-sensitivity detection kit based on WST-8 (water-soluble tetrazolium salt, chemical name: 2- (2-methoxy-4-nitrophenyl) -3- (4-nitrophenyl) -5- (2, 4-disulfophenyl) -2H-tetrazole monosodium salt), is an alternative method of an MTT method, adopts the water-soluble tetrazolium salt-WST-8 in the kit, and can be reduced by some dehydrogenases in mitochondria to generate orange formazan in the presence of an electronic coupling reagent. The more rapid the cell proliferation, the darker the color; the more cytotoxic, the lighter the color. The shade of the color and the number of cells were well linear for the same cells. The method comprises the following specific steps:
293T cells were cultured in 96-well plates and incubated with the polypeptides of Table 1 (dissolved in DMSO) in an amount of 25. mu.M in the culture medium, respectively. After 48 hours, the cell supernatant was replaced with cell culture medium containing 10% CCK-8 reagent, and the cells were incubated at 37 ℃ with 5% CO2The incubator is continued for 1 h. The Optical Density (OD) values per well at 450nm were recorded on a microplate reader (Thermo, Varioskan Flash). The solvent DMSO is used as a blank control (DMSO), tetrandrine (TET) is used as a control, and the content of tetrandrine in the culture medium is 3.125 μ M (tetrandrine has no cytotoxicity at the concentration, so that the concentration is used as a positive control).
As shown in FIG. 2, at 25 μ M (well above the measured IC)50Value), the polypeptide had no significant effect on the activity of the cells. Thus, the antiviral activity of the polypeptide is not associated with its cytotoxicity.
Example 3, Pep-3.1, Pep-3.2, Pep-3.3 and Pep-3.10 have good dose dependence on the inhibitory effect of EBOV.
Referring to the method in example 1, different concentrations of Pep-3.1, Pep-3.2, Pep-3.3 and Pep-3.10 of Table 1 were dissolved in DMSO respectively and mixed with EBOV-GP/HIV-luc pseudovirus respectively and added to 293T cells. After 48 hours, 293T cells were lysed and the anti-EBOV activity of the peptides was assessed by measuring luciferase activity. The solvent DMSO was used as a blank (DMSO), and the luciferase activity of the blank was taken as 100% of the cell viability. As can be seen from FIG. 3, Pep-3.1, Pep-3.2, Pep-3.3 and Pep-3.10 significantly inhibited the EBOV-GP/HIV-luc pseudovirus activity in a dose-dependent manner.
Example 4 the entry stage of Pep-3.3 action on the virus was determined by drug action time point experiments.
The specific inhibitory effect of the polypeptides Pep-3.1, Pep-3.2, Pep-3.3 and Pep-3.10 on EBOV-GP/HIV-luc pseudoviruses suggests that they may act as EBVO entry inhibitors. To verify this, the phase of action of the polypeptide in the viral infection cycle was studied by a Time of addition (TOA) assay. Since Pep-3.3 has the strongest specific inhibitory effect on EBOV-GP/HIV-luc pseudovirus in example 1, the mechanism of action of Pep-3.3 was mainly studied. The method comprises the following specific steps:
the day before infection, 293T cells were counted 6X 10 cells4One well was inoculated into a 96-well plate, and 50. mu.L of the EBOV-GP/HIV-luc infected cells of example 1 were added, respectively. Pep-3.3 of Table 1 (dissolved in DMSO to a content of 1X 10 in the medium (final concentration)) was added at time points 0, 2,4, 6, 8, 10, 12, 14 and 16h after infection (-1 h), during infection (0 h) and after infection-5mol·L-1) The EBOV entry inhibitor tetrandrine (TET) (dissolved in DMSO and contained in culture medium at 1 × 10%-7mol·L-1) Efavirenz (efavirenz, EFV), a non-nucleoside reverse transcriptase inhibitor (dissolved in DMSO at 1 x 10 in culture medium)-9mol·L-1) As a control, DMSO as a solvent control; 48h after infection, the luciferase activity of the reporter gene is detected to reflect the replication level of the recombinant virus.
The action link of the medicament can be preliminarily judged by measuring the failure time of the medicament during single EBOV infection. As shown in FIG. 4, Pep-3.3 showed very strong inhibition early in virus entry and no inhibition of virus infection after 4h (completion of the virus adsorption process). This is consistent with the duration of action of EBOV into the inhibitor tetrandrine. Efavirenz, a non-nucleoside reverse transcriptase inhibitor, still has inhibitory effect on viruses at 6 h. These results indicate that Pep-3.3 functions after binding of the virus to the host, but before membrane fusion of the virus to the host.
Example 5 in vitro determination of the binding Capacity of the polypeptide to the target protein GPc l Using the optical interference technique of the biofilm layer
The Ebola virus envelope surface glycoprotein GP is subjected to enzyme digestion treatment by host protease Cathepsin in an endocytosis body to become activated glycoprotein GPcl, and a receptor binding site is exposed. In order to verify that the polypeptide is bound to the target protein GPcl so as to specifically inhibit the entry of viruses, the binding capacity of the polypeptide and the target protein GPcl is measured in vitro by using a fiber biosensor-based biomembrane layer optical interference (BLI) technology. BLI technology enables real-time tracking of interactions between biomolecules and is an ideal choice for studying the interactions of proteins and other biomolecules. The method comprises the following specific steps:
the experiment was performed using a Ni-NTA (NTA) biosensor using an Octet RED96(ForteBio, Inc.) instrument. The following steps are mainly adopted for carrying out the experiment: 1) immersing the NAT sensor in a buffer solution for standing for 120s to reach equilibrium by a detection baseline; 2) incubating the protein on the sensor, moving the sensor probe into purified GPcl protein solution (50 μ g/ml) with His tag, standing for 600s, and fixing the protein on the NTA sensor; 3) moving the sensor to a buffer solution for standing for 120s to reach an equilibrium by detecting the baseline for the second time; 4) measuring a Kon value in combination with moving the sensor into the polypeptide solution and standing for 60 s; 5) dissociation the sensor was moved to the buffer solution and left to stand for 60s to obtain a Koff value. In the process of the processThe final kinetic curve was obtained using four different concentrations of the polypeptide. Experimental Data were analyzed using ForteBio Data Analysis software Data Analysis 9.0. Dissociation rate constant KD ═ Koff/Kon。
The abscissa in fig. 5 is the reaction time in seconds. The ordinate is the signal intensity in nm of the interaction of GPcl with the polypeptide. The results show that Pep-3.1, Pep-3.2, Pep-3.3, and Pep-3.10 of Table 1 are all able to bind GPcl protein, fitting dissociation rate constants KD of 119.8. mu.M, 97.4. mu.M, 69.7. mu.M, and 31. mu.M, respectively.
Sequence listing
<110> institute of medical and Biotechnology of Chinese academy of medical sciences
<120> cyclic polypeptide for anti-ebola virus or pharmaceutical salt thereof
<160> 4
<170> PatentIn version 3.5
<210> 1
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Cys Glu Tyr Phe Phe Trp Tyr Cys
1 5
<210> 2
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Cys Asp Tyr Phe Phe Trp Tyr Cys
1 5
<210> 3
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Cys His Tyr Phe Phe Val Tyr Cys
1 5
<210> 4
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Cys Tyr Tyr Phe Phe Val His Cys
1 5
Claims (10)
1. A cyclic polypeptide or a pharmaceutically acceptable salt thereof, characterized by: the amino acid sequence of the cyclic polypeptide is shown as the following (formula I):
X1X2X3X4X5X6X7X8(formula I) is shown in the specification,
in the formula I, X1To X8Are each an amino acid residue, said X1Is C, the X2Is E, D, H or Y, the X3Is Y, said X4Is F, the X5Is F, the X6Is W or V, said X7Is Y or H, said X8Is C; x in (formula I)1And X8Form disulfide bonds to form a ring.
2. The cyclic polypeptide or pharmaceutically acceptable salt thereof according to claim 1, wherein: the cyclic polypeptide is Pep-3.1 or Pep-3.10; the amino acid sequence of the Pep-3.1 is SEQ ID No.3 in the sequence table, and the amino acid sequence of the Pep-3.10 is SEQ ID No.4 in the sequence table.
3. A derivative of the cyclic polypeptide of claim 1 or 2 which is d1, d2, d3, d4 or d 5;
the d1 is a connector obtained by connecting an amino terminal protecting group at the amino terminal of the cyclic polypeptide and/or connecting a carboxyl terminal protecting group at the carboxyl terminal of the cyclic polypeptide;
d2 is a polypeptide which is obtained by adding amino acid residues at the amino terminal and/or the carboxyl terminal of the cyclic polypeptide and can be specifically combined with GPcl;
d3 is a polypeptide which is obtained by connecting oligopeptide at the amino terminal and/or the carboxyl terminal of the cyclic polypeptide and can be specifically combined with GPcl;
the d4 is a modified substance obtained by modifying the cyclic polypeptide by protein, polyethylene glycol or maleimide;
the d5 is a polypeptide which is obtained by connecting a lipophilic compound at the amino terminal and/or the carboxyl terminal of the cyclic polypeptide and can be specifically combined with GPcl.
Multimers of PM1 or PM 2:
PM1, a multimer formed from the cyclic polypeptide of claim 1 or 2, or a pharmaceutically acceptable salt thereof;
PM2, a multimer formed from the derivative of claim 3.
5. A composition comprising C1) and C2): C1) is C11), C12) or/and C13); c11) is the cyclic polypeptide of claim 1 or 2 or a pharmaceutically acceptable salt thereof; c12) is the derivative of claim 3; the C13) is the multimer of claim 4;
C2) a pharmaceutically acceptable carrier or adjuvant;
the composition has at least one of the following functions F1) -F3):
F1) resisting viruses;
F2) treating and/or preventing and/or adjunctively treating diseases caused by viral infection;
F3) inhibiting the entry of virus into cells.
6. The composition of claim 5, wherein: f1) -F3), the virus is Ebola virus or Marburg virus.
7, C11), C12), C13) or/and C14) for the preparation of at least one of the products E1) to E3):
c11) is the cyclic polypeptide of claim 1 or 2 or a pharmaceutically acceptable salt thereof; c12) is the derivative of claim 3; the C13) is the multimer of claim 4;
said C14) is the composition of claim 5 or 6;
the E1) is an antiviral product;
e2) is a product for treating and/or preventing and/or assisting in treating diseases caused by virus infection;
e3) is a product that inhibits the entry of viruses into cells.
8. Use according to claim 7, characterized in that: e1) -E3), the virus is ebola virus or marburg virus.
9. A pharmaceutical compound characterized by: the pharmaceutical compound is C11), C12), or C13);
c11) is the cyclic polypeptide of claim 1 or 2 or a pharmaceutically acceptable salt thereof; c12) is the derivative of claim 3; the C13) is the multimer of claim 4.
10. The pharmaceutical compound of claim 13, wherein: the pharmaceutical compound has at least one of the following U1) -U3):
u1) for antiviral;
u2) for the treatment and/or prophylaxis and/or adjuvant treatment of diseases caused by viral infections;
u3) for inhibiting viral entry into cells;
and/or the presence of a gas in the gas,
u1) -U3), the virus is ebola virus or marburg virus.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018100728036 | 2018-01-25 | ||
CN201810072803 | 2018-01-25 | ||
CN201810087839.1A CN108314706B (en) | 2018-01-25 | 2018-01-30 | Polypeptide specifically bound with Ebola virus activated envelope glycoprotein and application thereof in resisting viruses |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810087839.1A Division CN108314706B (en) | 2018-01-25 | 2018-01-30 | Polypeptide specifically bound with Ebola virus activated envelope glycoprotein and application thereof in resisting viruses |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113999284A true CN113999284A (en) | 2022-02-01 |
Family
ID=62890075
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111413917.0A Pending CN113999284A (en) | 2018-01-25 | 2018-01-30 | Cyclic polypeptide for resisting Ebola virus or medicinal salt thereof |
CN202010460222.7A Active CN111574588B (en) | 2018-01-25 | 2018-01-30 | Polypeptide and application thereof in resisting Ebola virus |
CN201810087839.1A Active CN108314706B (en) | 2018-01-25 | 2018-01-30 | Polypeptide specifically bound with Ebola virus activated envelope glycoprotein and application thereof in resisting viruses |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010460222.7A Active CN111574588B (en) | 2018-01-25 | 2018-01-30 | Polypeptide and application thereof in resisting Ebola virus |
CN201810087839.1A Active CN108314706B (en) | 2018-01-25 | 2018-01-30 | Polypeptide specifically bound with Ebola virus activated envelope glycoprotein and application thereof in resisting viruses |
Country Status (1)
Country | Link |
---|---|
CN (3) | CN113999284A (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115974973A (en) * | 2021-10-14 | 2023-04-18 | 浙江大学 | Polypeptide for inhibiting TRPM8 and application thereof |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105063044A (en) * | 2014-10-17 | 2015-11-18 | 苏州圣诺生物医药技术有限公司 | Active molecule capable of suppressing gene replication of Ebola virus and usage method thereof |
CN105663123A (en) * | 2016-03-24 | 2016-06-15 | 中国科学院微生物研究所 | Application of tebufenpyrad structure containing compound to preparation of Ebola virus infection resisting medicines |
CN105726525A (en) * | 2016-03-24 | 2016-07-06 | 中国科学院微生物研究所 | Application of compound containing Merochlorin A structure in preparation of medicines of resisting ebola virus infection |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002324753A1 (en) * | 2001-08-20 | 2003-07-09 | Myriad Genetics, Inc | Composition and method for treating viral infection |
GB0526120D0 (en) * | 2005-12-22 | 2006-02-01 | Novabiotics Ltd | Therapeutic peptides |
EP2451278A2 (en) * | 2009-07-10 | 2012-05-16 | Microbiotix, Inc. | Inhibitors of filovirus entry into host cells |
US10706955B2 (en) * | 2010-03-23 | 2020-07-07 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
CN105362284B (en) * | 2014-08-18 | 2020-01-24 | 中国医学科学院药物研究所 | Application of azithromycin and telithromycin in resisting ebola virus infection |
CN106636014A (en) * | 2015-10-28 | 2017-05-10 | 中国科学院上海巴斯德研究所 | Novel in-vitro and in-vivo infection model based on Ebola virus-like particles |
CN107033242B (en) * | 2017-04-16 | 2019-11-05 | 中国人民解放军军事医学科学院生物工程研究所 | A kind of monoclonal antibody and application of the anti-Ebola virus envelope glycoprotein of source of people |
-
2018
- 2018-01-30 CN CN202111413917.0A patent/CN113999284A/en active Pending
- 2018-01-30 CN CN202010460222.7A patent/CN111574588B/en active Active
- 2018-01-30 CN CN201810087839.1A patent/CN108314706B/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105063044A (en) * | 2014-10-17 | 2015-11-18 | 苏州圣诺生物医药技术有限公司 | Active molecule capable of suppressing gene replication of Ebola virus and usage method thereof |
CN105663123A (en) * | 2016-03-24 | 2016-06-15 | 中国科学院微生物研究所 | Application of tebufenpyrad structure containing compound to preparation of Ebola virus infection resisting medicines |
CN105726525A (en) * | 2016-03-24 | 2016-07-06 | 中国科学院微生物研究所 | Application of compound containing Merochlorin A structure in preparation of medicines of resisting ebola virus infection |
Also Published As
Publication number | Publication date |
---|---|
CN108314706A (en) | 2018-07-24 |
CN111574588B (en) | 2021-11-09 |
CN108314706B (en) | 2020-06-16 |
CN111574588A (en) | 2020-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109125323B (en) | Application of berbamine dihydrochloride in preparation of Ebola virus inhibitor | |
CN111643656B (en) | Broad-spectrum coronavirus membrane fusion inhibitor and application thereof in resisting AIDS virus | |
JP4682251B2 (en) | HIV fusion inhibitor peptides with improved biological properties | |
US7335727B2 (en) | Pharmaceutical used for treating HIV infection, the composition and uses thereof | |
KR20100016142A (en) | Novel formulations for delivery of antiviral peptide therapeutics | |
CN114736272B (en) | Method for optimizing virus membrane fusion inhibitor, broad-spectrum anti-coronavirus lipopeptide and application | |
CN101466392A (en) | Pharmaceutical composition for preventing or curing HIV infection and use thereof | |
CN115746148A (en) | Protein with coronavirus RBD and membrane fusion inhibiting polypeptide and application of protein as coronavirus inhibitor | |
US20210277068A1 (en) | Lipopeptide for potently inhibiting hiv, derivative thereof, pharmaceutical composition thereof and use thereof | |
CN102816215B (en) | Smallish polypeptide capable of inhibiting HIV and medicinal use thereof | |
CN111574588B (en) | Polypeptide and application thereof in resisting Ebola virus | |
KR20100080812A (en) | Methods of synthesis for therapeuthic anti-hiv peptides | |
CN115996741A (en) | CXCR4 inhibitors for the treatment of acute respiratory distress syndrome and viral infections | |
CN109535232B (en) | Polypeptide, preparation method thereof and application of polypeptide in inhibiting HIV (acquired immune deficiency syndrome virus) | |
CN116444644A (en) | Broad-spectrum virus membrane fusion inhibitor and preparation method and application thereof | |
US20100021427A1 (en) | Use of Antiviral Peptides For Treatment of Infections Caused by Drug-Resistant HIV | |
JP4332618B2 (en) | Anti-HIV agent | |
FR2968663A1 (en) | PEPTIDES AND ANTIVIRAL DRUG | |
CN115724919A (en) | Novel membrane fusion inhibitor for strongly inhibiting AIDS virus and drug-resistant strains thereof and pharmaceutical application thereof | |
CN117186187A (en) | Anti-respiratory syncytial virus membrane fusion inhibitor and pharmaceutical application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |